An Advanced Tool for T Cell Analysis Using Microfluidics Organization: GigaGen Inc. PI: David S. Johnson, Ph.D. Better methods for discovery and monitoring of immune system biomarkers could improve treatment of a variety of diseases and conditions, including cancer, autoimmune diseases, allergies, transplant rejection, and infectious diseases. We are building a novel technology that uses microfluidics and DNA sequencing to understand the immune system in unprecedented ways.
Public Health Relevance Statement: PROJECT NARRATIVE Project Title: An Advanced Tool for T Cell Analysis Using Microfluidics Organization: GigaGen Inc. PI: David S. Johnson, Ph.D. Better methods for discovery and monitoring of immune system biomarkers could improve treatment of a variety of diseases and conditions, including cancer, autoimmune diseases, allergies, transplant rejection, and infectious diseases. We are building a novel technology that uses microfluidics and DNA sequencing to understand the immune system in unprecedented ways.
Project Terms: Antibodies; antibody conjugate; Antigens; Area; Autoimmune Diseases; base; Biological Markers; blind; Capital; Cataloging; Catalogs; Cell Line; Cell physiology; Cell Separation; Cells; Chemistry; Clinical; clinically relevant; commercialization; Communicable Diseases; cytokine; deep sequencing; Detection; Devices; Diagnostic; Disease; DNA Sequence; Doctor of Philosophy; Elements; Fluorescence-Activated Cell Sorting; fluorophore; Genes; Genomics; Genotype; Goals; Graft Rejection; Hour; Human; Hypersensitivity; Immune; Immune system; Immunologist; Immunology; improved; interest; Interferon Type II; Interleukin-10; Interleukin-17; Interleukin-2; Legal patent; Licensing; Malignant Neoplasms; Market Research; Marketing; Measures; Methods; Microfluidics; Modeling; Monitor; new technology; Phase; Phenotype; Population; prevent; product development; Reagent; Receiver Operating Characteristics; Regulatory T-Lymphocyte; research study; RNA Sequences; Sampling; Scientist; Sensitivity and Specificity; Sequoia; Small Business Innovation Research Grant; Specialist; T cell therapy; T-Cell Receptor; T-Lymphocyte; Technology; Technology Transfer; Testing; Time; tool; transcriptome sequencing; Tumor Necrosis Factor-alpha; United States National Institutes of Health; validation studies; Variant; Work
